TY - JOUR AU - Martinez, V. AU - Azzopardi, J. G. PY - 1979 DA - 1979// TI - Invasive lobular carcinoma of the breast: incidence and variants JO - Histopathology VL - 3 ID - Martinez1979 ER - TY - JOUR AU - Li, C. I. AU - Anderson, B. O. AU - Daling, J. R. AU - Moe, R. E. PY - 2003 DA - 2003// TI - Trends in incidence rates of invasive lobular and ductal breast carcinoma JO - JAMA VL - 289 ID - Li2003 ER - TY - JOUR AU - Li, C. I. AU - Daling, J. R. PY - 2007 DA - 2007// TI - Changes in breast cancer incidence rates in the United States by histologic subtype and race/ethnicity, 1995 to 2004 JO - Cancer Epidemiol Biomark Prev VL - 16 ID - Li2007 ER - TY - JOUR AU - Ferlay, J. AU - Colombet, M. AU - Soerjomataram, I. AU - Mathers, C. AU - Parkin, D. M. AU - Pineros, M. PY - 2019 DA - 2019// TI - Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods JO - Int J Cancer VL - 144 ID - Ferlay2019 ER - TY - JOUR AU - Pestalozzi, B. C. AU - Zahrieh, D. AU - Mallon, E. AU - Gusterson, B. A. AU - Price, K. N. AU - Gelber, R. D. PY - 2008 DA - 2008// TI - Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials JO - J Clin Oncol VL - 26 ID - Pestalozzi2008 ER - TY - JOUR AU - Rakha, E. A. AU - El-Sayed, M. E. AU - Powe, D. G. AU - Green, A. R. AU - Habashy, H. AU - Grainge, M. J. PY - 2008 DA - 2008// TI - Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes JO - Eur J Cancer VL - 44 ID - Rakha2008 ER - TY - JOUR AU - Metzger Filho, O. AU - Giobbie-Hurder, A. AU - Mallon, E. AU - Gusterson, B. AU - Viale, G. AU - Winer, E. P. PY - 2015 DA - 2015// TI - Relative effectiveness of letrozole compared with tamoxifen for patients with lobular carcinoma in the BIG 1-98 trial JO - J Clin Oncol VL - 33 ID - Metzger Filho2015 ER - TY - JOUR AU - Sikora, M. J. AU - Cooper, K. L. AU - Bahreini, A. AU - Luthra, S. AU - Wang, G. AU - Chandran, U. R. PY - 2014 DA - 2014// TI - Invasive lobular carcinoma cell lines are characterized by unique estrogen-mediated gene expression patterns and altered tamoxifen response JO - Cancer Res VL - 74 ID - Sikora2014 ER - TY - STD TI - NICE. Early and locally advanced breast cancer: diagnosis and management. Online: National Institute for Health and Care Excellence; 2018 [NICE Pathway]. Available from: https://www.nice.org.uk/guidance/ng101. UR - https://www.nice.org.uk/guidance/ng101 ID - ref9 ER - TY - JOUR AU - Cardoso, F. AU - Kyriakides, S. AU - Ohno, S. AU - Penault-Llorca, F. AU - Poortmans, P. AU - Rubio, I. T. PY - 2019 DA - 2019// TI - Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-updagger JO - Ann Oncol VL - 30 ID - Cardoso2019 ER - TY - JOUR AU - Wolff, A. C. AU - Hammond, M. E. H. AU - Allison, K. H. AU - Harvey, B. E. AU - Mangu, P. B. AU - Bartlett, J. M. S. PY - 2018 DA - 2018// TI - Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update JO - J Clin Oncol VL - 36 ID - Wolff2018 ER - TY - JOUR AU - Denduluri, N. AU - Chavez-MacGregor, M. AU - Telli, M. L. AU - Eisen, A. AU - Graff, S. L. AU - Hassett, M. J. PY - 2018 DA - 2018// TI - Selection of optimal adjuvant chemotherapy and targeted therapy for early breast Cancer: ASCO clinical practice guideline focused update JO - J Clin Oncol VL - 36 ID - Denduluri2018 ER - TY - JOUR AU - Bose, R. AU - Kavuri, S. M. AU - Searleman, A. C. AU - Shen, W. AU - Shen, D. AU - Koboldt, D. C. PY - 2013 DA - 2013// TI - Activating HER2 mutations in HER2 gene amplification negative breast cancer JO - Cancer Discov VL - 3 ID - Bose2013 ER - TY - JOUR AU - Hanker, A. AU - Koch, J. AU - Ye, D. AU - Sliwoski, G. AU - Sheehan, J. AU - Kinch, L. PY - 2019 DA - 2019// TI - Abstract PD3-05: Co-occurring gain-of-function mutations in HER2 and HER3 cooperate to enhance HER2/HER3 binding, HER-dependent signaling, and breast cancer growth JO - Cancer Res VL - 79 ID - Hanker2019 ER - TY - JOUR AU - Eroglu, Z. AU - Tagawa, T. AU - Somlo, G. PY - 2014 DA - 2014// TI - Human epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancer JO - Oncologist VL - 19 ID - Eroglu2014 ER - TY - JOUR AU - Hynes, N. E. AU - MacDonald, G. PY - 2009 DA - 2009// TI - ErbB receptors and signaling pathways in cancer JO - Curr Opin Cell Biol VL - 21 ID - Hynes2009 ER - TY - JOUR AU - Junttila, T. T. AU - Akita, R. W. AU - Parsons, K. AU - Fields, C. AU - Lewis Phillips, G. D. AU - Friedman, L. S. PY - 2009 DA - 2009// TI - Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941 JO - Cancer Cell VL - 15 ID - Junttila2009 ER - TY - JOUR AU - Mishra, R. AU - Patel, H. AU - Alanazi, S. AU - Yuan, L. AU - Garrett, J. T. PY - 2018 DA - 2018// TI - HER3 signaling and targeted therapy in cancer JO - Oncol Rev VL - 12 ID - Mishra2018 ER - TY - JOUR AU - Jaiswal, B. S. AU - Kljavin, N. M. AU - Stawiski, E. W. AU - Chan, E. AU - Parikh, C. AU - Durinck, S. PY - 2013 DA - 2013// TI - Oncogenic ERBB3 mutations in human cancers JO - Cancer Cell VL - 23 ID - Jaiswal2013 ER - TY - JOUR AU - Ping, Z. AU - Siegal, G. P. AU - Harada, S. AU - Eltoum, I. E. AU - Youssef, M. AU - Shen, T. PY - 2016 DA - 2016// TI - ERBB2 mutation is associated with a worse prognosis in patients with CDH1 altered invasive lobular cancer of the breast JO - Oncotarget VL - 7 ID - Ping2016 ER - TY - JOUR AU - Ross, J. S. AU - Wang, K. AU - Sheehan, C. E. AU - Boguniewicz, A. B. AU - Otto, G. AU - Downing, S. R. PY - 2013 DA - 2013// TI - Relapsed classic E-cadherin (CDH1)-mutated invasive lobular breast cancer shows a high frequency of HER2 (ERBB2) gene mutations JO - Clin Cancer Res VL - 19 ID - Ross2013 ER - TY - JOUR AU - Griffith, O. L. AU - Spies, N. C. AU - Anurag, M. AU - Griffith, M. AU - Luo, J. AU - Tu, D. PY - 2018 DA - 2018// TI - The prognostic effects of somatic mutations in ER-positive breast cancer JO - Nat Commun VL - 9 ID - Griffith2018 ER - TY - JOUR AU - Ross, J. S. AU - Gay, L. M. AU - Wang, K. AU - Ali, S. M. AU - Chumsri, S. AU - Elvin, J. A. PY - 2016 DA - 2016// TI - Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: an emerging opportunity for anti-HER2 targeted therapies JO - Cancer VL - 122 ID - Ross2016 ER - TY - JOUR AU - Desmedt, C. AU - Zoppoli, G. AU - Gundem, G. AU - Pruneri, G. AU - Larsimont, D. AU - Fornili, M. PY - 2016 DA - 2016// TI - Genomic characterization of primary invasive lobular breast cancer JO - J Clin Oncol VL - 34 ID - Desmedt2016 ER - TY - JOUR AU - Ciriello, G. AU - Gatza, M. L. AU - Beck, A. H. AU - Wilkerson, M. D. AU - Rhie, S. K. AU - Pastore, A. PY - 2015 DA - 2015// TI - Comprehensive molecular portraits of invasive lobular breast cancer JO - Cell VL - 163 ID - Ciriello2015 ER - TY - JOUR AU - Pereira, B. AU - Chin, S. F. AU - Rueda, O. M. AU - Vollan, H. K. AU - Provenzano, E. AU - Bardwell, H. A. PY - 2016 DA - 2016// TI - The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes JO - Nat Commun VL - 7 ID - Pereira2016 ER - TY - JOUR AU - Razavi, P. AU - Chang, M. T. AU - Xu, G. AU - Bandlamudi, C. AU - Ross, D. S. AU - Vasan, N. PY - 2018 DA - 2018// TI - The genomic landscape of endocrine-resistant advanced breast cancers JO - Cancer Cell VL - 34 ID - Razavi2018 ER - TY - JOUR AU - Kadota, K. AU - Nakai, Y. AU - Shimizu, K. PY - 2008 DA - 2008// TI - A weighted average difference method for detecting differentially expressed genes from microarray data JO - Algorithms Mol Biol VL - 3 ID - Kadota2008 ER - TY - JOUR AU - Curtis, C. AU - Shah, S. P. AU - Chin, S. F. AU - Turashvili, G. AU - Rueda, O. M. AU - Dunning, M. J. PY - 2012 DA - 2012// TI - The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups JO - Nature VL - 486 ID - Curtis2012 ER - TY - JOUR AU - Ferrari, A. AU - Vincent-Salomon, A. AU - Pivot, X. AU - Sertier, A. S. AU - Thomas, E. AU - Tonon, L. PY - 2016 DA - 2016// TI - A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers JO - Nat Commun VL - 7 ID - Ferrari2016 ER - TY - JOUR AU - Desmedt, C. AU - Haibe-Kains, B. AU - Wirapati, P. AU - Buyse, M. AU - Larsimont, D. AU - Bontempi, G. PY - 2008 DA - 2008// TI - Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes JO - Clin Cancer Res VL - 14 ID - Desmedt2008 ER - TY - STD TI - Sareyeldin RM, Gupta I, Al-Hashimi I, Al-Thawadi HA, Al Farsi HF, Vranic S, et al. Gene expression and miRNAs profiling: function and regulation in human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Cancers (Basel). 2019;11(5):646. ID - ref32 ER - TY - JOUR AU - Creighton, C. J. AU - Hilger, A. M. AU - Murthy, S. AU - Rae, J. M. AU - Chinnaiyan, A. M. AU - El-Ashry, D. PY - 2006 DA - 2006// TI - Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors JO - Cancer Res VL - 66 ID - Creighton2006 ER - TY - JOUR AU - Rees, M. G. AU - Seashore-Ludlow, B. AU - Cheah, J. H. AU - Adams, D. J. AU - Price, E. V. AU - Gill, S. PY - 2016 DA - 2016// TI - Correlating chemical sensitivity and basal gene expression reveals mechanism of action JO - Nat Chem Biol VL - 12 ID - Rees2016 ER - TY - JOUR AU - Rajapakse, V. N. AU - Luna, A. AU - Yamade, M. AU - Loman, L. AU - Varma, S. AU - Sunshine, M. PY - 2018 DA - 2018// TI - CellMinerCDB for integrative cross-database genomics and pharmacogenomics analyses of cancer cell lines JO - iScience VL - 10 ID - Rajapakse2018 ER - TY - JOUR AU - Basu, A. AU - Bodycombe, N. E. AU - Cheah, J. H. AU - Price, E. V. AU - Liu, K. AU - Schaefer, G. I. PY - 2013 DA - 2013// TI - An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules JO - Cell VL - 154 ID - Basu2013 ER - TY - STD TI - Ma CX, Bose R, Gao F, Freedman RA, Pegram MD, Blackwell K, et al. Phase II trial of neratinib for HER2 mutated, non-amplified metastatic breast cancer (HER2(mut) MBC). J Clin Oncol. 2016;34(15 suppl):516. ID - ref37 ER - TY - JOUR AU - Syed, B. M. AU - Green, A. R. AU - Paish, E. C. AU - Soria, D. AU - Garibaldi, J. AU - Morgan, L. PY - 2013 DA - 2013// TI - Biology of primary breast cancer in older women treated by surgery: with correlation with long-term clinical outcome and comparison with their younger counterparts JO - Br J Cancer VL - 108 ID - Syed2013 ER -